Hosted on MSN11mon
Sellas reports positive Phase 2 data from AML study, files for patentSLS also said it has filed a provisional patent application related to the ASXL1 mutation, a highly prevalent gene mutation in myeloid malignancies and solid tumors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback